Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()
DOP22: UC-related and segment-specific properties of patient-derived colonic organoids

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Suzuki*1, H. Shimizu1, M. Kawai1, J. Takahashi1, S. Anzai1, A. Kawamoto1, S. Nagata1, Y. Hiraguri1, S. Yui1, K. Tsuchiya1, T. Nakamura1, K. Ohtsuka1, K. Ohtsuka1, R. Okamoto1, M. Watanabe1

1Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

DOP23: Myenteric plexitis and post-operative recurrence in Crohn’s disease: the role of enteric glial cells and ICAM-1

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Le Berre*1, J. Pabois1, T. Durand1, E. Durieu1, M. Rolli-Derkinderen1, C. Bossard2, J. Podevin3, M. Neunlist1, I. Neveu1, P. Naveilhan1, A. Bourreille1,4

1Nantes University Hospital, UMR Inserm 1235 – TENS, Gastroenterology department, Institut des Maladies de l’Appareil Digestif, Nantes, France, 2Nantes University Hospital, Pathology department, Nantes, France, 3Nantes University Hospital, Digestive surgery department, Institut des Maladies de l’Appareil Digestif, Nantes, France, 4Nantes University Hospital, CIC, INSERM 1413, Nantes, France

DOP24: Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Weder*1, W. T. Van Haaften2, K. Baebler1, G. Rogler3, G. Dijkstra4, P. H. Imenez Silva5, Y. Wang5, C. De Vallière3, C. Wagner5, I. Frey-Wagner3, K. Seuwen6, P. Ruiz3, M. Hausmann3

1University of Zurich, Zurich, Switzerland, 2University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 3University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, 4University of Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 5University of Zurich, Institute of Physiology, Zurich, Switzerland, 6Novartis Institutes for Biomedical Research, Basel, Switzerland

DOP25: Unravelling vedolizumab mechanism of action in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Veny*1, A. Garrido1, H. Bassolas-Molina1, M. C. Masamunt1, M. Esteller1, M. Arroyes1, A. M. Corraliza1, E. Tristán2, A. Fernández-Clotet1, I. Ordás1, E. Ricart1, M. Esteve2, J. Panés1, A. Salas1

1IDIBAPS, Hospital Clínic, CIBERehd, Department of Gastroenterology, Barcelona, Spain, 2Hospital Universitari Mutua Terrassa, Department of Gastroenterology, Terrassa, Spain

DOP26: Biological therapy increases NCR+ ILC3 levels in IBD patients

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Creyns*1,2, B. Verstockt2,3, J. Cremer1,2, V. Ballet3, M. Ferrante2,3, S. Vermeire2,3, J. Ceuppens1, G. Van Assche2,3, C. Breynaert1

1KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

DOP27: Sequencing-based hematopoietic miRNA landscape reveals common and distinct features of autoimmune inflammatory phenotypesECCO '19 Copenhagen
Year: 2019
Authors:

S. Juzenas*1,2, M. Hübenthal1, S. Zeißig3, N. Strüning4, A. Keller5, D. Schulte6, M. D’Amato7,8, M. Lindqvist9, J. Kupčinskas2,11, S. Schreiber1,12, J. Halfvarson13, G. Hemmrich-Stanisak1, A. Franke1

1Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, 2Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania, 3Department of Medicine, TU Dresden, Dresden, Germany, 4Department of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany, 5Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany, 6Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany, 7Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden, 8Basque Foundation for Science, BioCruces Health Research Institute and IKERBASQUE, Bilbao, Spain, 9Department of Medical Sciences, Örebro University, Örebro, Sweden, 11Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania, 12Department of Internal Medicine, University Hospital Schleswig-Holstein, KIel, Germany, 13Department of Gastroenterology, Örebro University, Örebro, Sweden

DOP28: Maternal obstetric outcomes in women with IBD compared with the general population

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Lever1, T. Glanville1, C. Selinger*2

1Leeds Teaching Hospitals NHS Trust, Leeds, UK, 2Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, UK

DOP29: Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Moens*1,2, C. van der Woude3, M. Julsgaard4, S. Sebastian5,6, N. Arebi7, M. Alzinaty7, E. Humblet8, K. B. Kok9, J. Sheridan10, C. Gilletta De Saint-Joseph11, S. Nancey12, J-F. Rahier13, P. Bossuyt14, A. Cremer15, S. Dewit16, C. Eriksson17, F. Hoentjen18, T. Krause19, E. Louis20, E. Macken21, Z. Milenkovic22, J. Nijs23, A. Posen24, A. Van Hootegem25, W. Van Moerkercke26, S. Vermeire1,2, A. Bar-Gil Shitrit27, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2Catholic University Leuven, Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 4Aarhus University Hospital, Department of Gastroenterology and Hepatology, Aarhus, Denmark, 5Hull and East Yorkshire NHS Trust, IBD Unit, Hull, UK, 6University of Hull and York, Hull York Medical School, Hull, UK, 7St. Marks Hospital, Department of Gastroenterology, London, UK, 8Ziekenhuis Oost-Limburg – Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 9Barts Health NHS Trust, Department of Gastroenterology, London, UK, 10St. Vincent’s University Hospital, Department of Gastroenterology, Dublin, Ireland, 11Hôpital Rangueil, Department of Gastroenterology, Toulouse, France, 12CHU Lyon, Department of Gastroenterology and Hepatology, Lyon, France, 13CHU UCL Namur, Université catholique de Louvain, Deparment of Gastroenterology, Yvoir, Belgium, 14Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 15Hôpital Erasme, Université Libre de Bruxelles, Department of Gastroenterology, Brussels, Belgium, 16Mariaziekenhuis Noord-Limburg, Department of Gastroenterology, Overpelt, Belgium, 17Faculty of Medicine and Health Orebro University, Department of Gastroenterology, Orebro, Sweden, 18Radboud UMC, Department of Gastroenterology, Nijmegen, The Netherlands, 19Opernstrasse, Department of Gastroenterology, Kassel, Germany, 20CHU Liège, Department of Gastroenterology, Liège, Belgium, 21Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 22Military Medical Academy Belgrade, Department of Gastroenterology, Belgrade, Serbia, 23Sint-Trudo Ziekenhuis, Department of Gastroenterology, St-Truiden, Belgium, 24AZ Vesalius, Department of Gastroenterology, Tongeren, Belgium, 25AZ Klina, Department of Gastroenterology, Brasschaat, Belgium, 26AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 27Shaare Zedek Medical Center, Hebrew University Jerusalem, Digestive diseases institute, Jerusalem, Israel

DOP30: Factors associated with life satisfaction in people with Crohn’s disease and ulcerative colitis: results from the national 2018 Crohn’s and Colitis UK Inflammatory Bowel Disease Quality of Life Survey

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Rowse*1, S. Hollobone2, S. Afhim2, P. Oliver3

1University of Sheffield, Clinical Psychology Unit, Sheffield, UK, 2Crohn’s and Colitis UK, St Albans, UK, 3University of Sheffield, Academic Unit of Primary Medical Care, Sheffield, UK

DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD?

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Atia1, G. Focht1, A. Assa2, B. Yerushalmi3, R. Shaoul4, D. S. Shouval5, A. Bar-Gil Shitrit6, B. Koslowsky6, I. Dotan7, R. Kariv8, E. Lavon8, D. Turner*1

1Institute of Pediatric Gastroenterology, The Hebrew University of Jerusalem, Jerusalem, Israel, 2Schneider Children’s Hospital, Petach Tikva, Israel, 3Soroka University Medical Center and Faculty of Pediatric Gastroenetrology Unit, Health Sciences, Beer-Sheva, Israel, 4Pediatric Gastroenterology Institute, Ruth Children’s Hospital, Rambam Medical Center, Haifa, Israel, 5Pediatric Gastroenterology Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Ramat gan, Israel, 6Digestive diseases institute, Shaare Zedek Medical Center, Jerusalem, Israel, 7Division of Gastroenterology, Rabin Medical Center, Sackler Faculty of Medicine, Petach Tikva, Israel, 8Health Division, Maccabi Healthcare Services, Jerusalem, Israel

DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Hisamatsu*1, S. Kato2, R. Kunisaki3, M. Matsuura4, M. Nagahori5, S. Motoya6, M. Esaki7, N. Fukata8, S. Inoue9, T. Sugaya10, H. Sakuraba11, F. Hirai12, K. Watanabe13,14, T. Kanai15, M. Naganuma15, H. Nakase16, Y. Suzuki17, M. Watanabe5, T. Hibi18, M. Nojima19, T. Matsumoto20, DIAMOND2 Study Group1

1Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, 2Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Saitama, Japan, 3Yokohama City University Medical Center, Inflammatory Bowel Disease Centre, Kanagawa, Japan, 4Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, 5Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 6Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, 7Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 8Kansai Medical University, Third Department of Internal Medicine, Osaka, Japan, 9Kobe City Medical Center General Hospital, Departments of Gastroenterology, Hyogo, Japan, 10Japan Red Cross Ashikaga Hospital, Department of Internal Medicine, Tochigi, Japan, Japan, 11Hirosaki University Graduate School of Medicine, Department of Gastroenterology and Hematology, Hirosaki, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, 14Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Japan, 15Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, 16Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan, 17Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, 18Kitasato University, Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 19Institute of Medical Science Hospital, University of Tokyo, Center for Translational Research, Tokyo, Japan, 20Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan

DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s disease : a multi-centre Belgian cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Liefferinckx*1, B. Verstockt2, A. Gils3, M. Noman2, C. Van Kemseke4, E. Macken5, M. De Vos6, W. Van Moerkercke7, J-F. Rahier8, P. Bossuyt9, J. Dutré10, E. Humblet11, D. Staessen12, H. Peters13, P. Van Hootegem14, E. Louis4, D. Franchimont1, F. Baert15, S. Vermeire2

1Hopital Erasme – ULB, Department of Gastroenterology, Brussels, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 4Centre Hospitalier Universitaire Sart-Tilman – ULG, Department of Gastroenterology, Liège, Belgium, 5Universiteit ziekenhuis Antwerpen – UZA, Department of Gastroenterology, Antwerpen, Belgium, 6Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, 7AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 8Centre Hospitalier Universitaire Mont-Godinne – UCL, Department of Gastroenterology, Yvoir, Belgium, 9Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 10Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 11Ziekenhuis Oost-Limburg – Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 12GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, 13Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Gent, Belgium, 14Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Brugge, Belgium, 15AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium

DOP34: Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Aloi*1, M. Bramuzzo2, L. Norsa3, S. Arrigo4, M. Distante5, E. Miele6, A. Agrusti2, C. Romano7, C. Giobbi5, R. Panceri8, L. D’Antiga3, S. Cucchiara5, P. Alvisi9, SIGENP IBD Working Group1

1Sapienza University of Rome, Department of Pediatrics, Pediatric Gastroenterology Unit, Rome, Italy, 2Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 3Ospedale Papa Giovanni XXIII, Pediatric Gastroenterology Hepatology and Nutrition, Bergamo, Italy, 4Istituto Giannina Gaslini, Department of Gastroenterology and Endoscopy, Genoa, Italy, 5Sapienza University of Rome, Department of Pediatric Gastroenterology, Rome, Italy, 6University of Naples ‘Federico II’, Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, 7University of Messina, Department of Pediatric Gastroenterology and Endoscopy, Messina, Italy, 8San Gerardo Hospital, Monza, Italy, 9Maggiore Hospital, Bologna, Italy

DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype

ECCO '19 Copenhagen

Year: 2019
Authors:

R. S. Choung*1, F. Petralia2, J. Torres3,4, T. Sato5, X-j. Li6, P. Wang2, S. Telesco5, C. Porter7, R. Laird7, R. Gutierrez7, F. Princen6, S. Plevy5, R. Strauss5, M. Riddle7, J. Murray1, J. F. Colombel3, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) Study Group1

1Mayo Clinic, Gastroenterology and Hepatology, Rochester, USA, 2Icahn School of Medicine, Genetics and Genomic Sciences, New York, USA, 3Icahn School of Medicine at Mount Sinai, New York, USA, 4Hospital Beatriz Ângelo, Lisbon, Portugal, 5Janssen R&D, Spring House, USA, 6Prometheus Laboratories Inc., San Diego, USA, 7Naval Medical Research Center, Silver Spring, USA

DOP36: Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Braun1, A. Di Segni1, M. BenShoshan1, S. Neuman1, O. Picard1, K. Sosnovski1, G. Efroni1, B. Weiss1, D. Yablecovitch1, A. Lahat1, R. Eliakim1, U. Kopylov1, S. Ben-Horin1, Y. Haberman*1,2, Israeli IBD Research Nucleus (IIRN)1

1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, USA

DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, E. Mertens1, A. Outtier1, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium

DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, S. Verstockt3, P. Sudahakar2,4,5, J. Dehairs6, H. Blevi2, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium, 4Earlham Institute, Norwich, UK, 5Quadram Institute, Norwich, Belgium, 6Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium

DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Al Draiweesh*1,2, C. Ma1,3, M. Alkhattabi1, N. Chande1, B. G. Feagan1, J. C. Gregor1, R. Khanna1, P. Marotta1, A. Sandhu1, K. Qumosani1, A. Teriaky1, M. Brahmania1, V. Jairath1,4,5

1Western University, Department of Medicine, Division of Gastroenterology, London, Ontario, Canada, 2King Fahad Specialist Hospital, Department of Medicine, Division of Gastroenterology, Dammam, Saudi Arabia, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada, 4King Abdulaziz University, Department of Medicine, Rabigh, Saudi Arabia, 5Western University, Department of Epidemiology and Biostatistics, London, Ontario, Canada

DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Meyer*1, J. Rudant2, J. Drouin2, A. Weill2, F. Carbonnel3, J. Coste2

1Caisse Nationale Assurance Maladie, Paris, France, 2Caisse Nationale de l’Assurance Maladie, Paris, France, 3Hopital Bicetre, Le Kremlin Bicetre, France

DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Chiorean1, C. Su2, K. Matsuoka3, A. Orlando4, A. J. Thorpe2, C. I. Nduaka2, D. S. Chapman5, D. A. Woodworth2, N. Lawendy2, G. S. Friedman2, R. D. Cohen*6

1Virginia Mason Medical Center, Seattle, WA, USA, 2Pfizer Inc., Collegeville, PA, USA, 3Toho University Sakura Medical Center, Sakura, Chiba, Japan, 4University of Palermo, IBD Unit, Palermo, Italy, 5Pfizer Inc., New York, NY, USA, 6University of Chicago Medicine, Chicago, IL, USA

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 182 ()